Made Scientific Partners with Regenicin to Advance NovaDerm Autologous Skin Substitute Toward FDA Approval
核心洞察
Made Scientific (搜索) will serve as the manufacturing partner for NovaDerm (搜索), providing end-to-end GMP clinical production services at its Princeton facility to support Regenicin (搜索)'s IND submission and upcoming clinical trial.
NovaDerm (搜索) is a breakthrough autologous cultured skin substitute that utilizes patients' own skin cells to create living, regenerative skin for treating severe burns (搜索) and chronic wounds (搜索).
The tissue-engineered skin graft requires less tissue harvesting and reduces hospitalization days for patients compared to traditional treatments.
Made Scientific (搜索), a U.S.-based cell therapy contract development and manufacturing organization (CDMO), has announced a strategic manufacturing partnership with Regenicin (搜索) to advance NovaDerm (搜索), an autologous cultured skin substitute, toward FDA Orphan product approval for severe burns (搜索) and chronic wounds (搜索). The collaboration positions NovaDerm for its upcoming Investigational New Drug (IND) submission and first-in-human clinical trial.
Manufacturing Partnership Details
Under the agreement, Made Scientific (搜索) will provide comprehensive end-to-end services at its Princeton, New Jersey GMP facility, establishing a clear pathway from technology transfer through GMP clinical production and regulatory support. The partnership addresses the complex manufacturing requirements for patient-specific autologous therapies, which demand exceptional consistency and traceability throughout the production process.
"We are proud to work with Regenicin (搜索) to advance NovaDerm (搜索) into the clinic," said Syed T. Husain, Chairman and CEO of Made Scientific (搜索). "This collaboration reflects the strength of our manufacturing platform and our ability to execute complex autologous programs with the precision and regulatory rigor required for clinical success."
NovaDerm Technology and Clinical Benefits
NovaDerm (搜索) represents a breakthrough in regenerative medicine as a tissue-engineered skin graft that utilizes patients' own skin cells to create living, regenerative skin tissue. The autologous approach offers significant clinical advantages over traditional treatments, requiring less tissue harvesting from patients and reducing hospitalization duration.
Dr. K. E. Castro, PhD, Director of Clinical Studies at Regenicin (搜索), emphasized the manufacturing challenges inherent in patient-specific treatments: "Manufacturing a patient-specific treatment like NovaDerm (搜索) requires a level of consistency and traceability that few CDMOs can deliver. Made Scientific (搜索)'s proven expertise in autologous manufacturing gives us confidence as we move toward our IND submission and first-in-human clinical trial."
Regulatory Pathway and Market Positioning
The partnership supports Regenicin (搜索)'s pursuit of FDA Orphan product approval, a designation that provides regulatory incentives for treatments addressing rare diseases or conditions affecting fewer than 200,000 patients in the United States. This regulatory pathway reflects the significant unmet medical need in severe burn and chronic wound treatment.
Regenicin (搜索), founded in 2010, has assembled a management team with extensive experience in developing and commercializing innovative medical devices and biotechnology products. The company's focus on regenerative cell therapies aligns with the growing field of tissue engineering and personalized medicine.
Manufacturing Capabilities and Infrastructure
Made Scientific (搜索) specializes in the development, manufacturing, and release of both autologous and allogeneic cell therapy products for clinical and commercial supply. The company combines specialized CDMO agility with deep technical expertise, supported by its strategic backer GC Corporation (搜索), a global pharmaceutical and biotechnology leader.
The Princeton facility's state-of-the-art infrastructure and continued technology investments position the partnership to meet the stringent requirements for autologous cell therapy manufacturing, including the complex logistics of patient-specific product development and delivery.